# Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

> **NCT06423937** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 129 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab

## Key facts

- **NCT ID:** NCT06423937
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423937, "Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06423937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*